Moxibustion as an adjuvant therapy for heart failure: A systematic review and meta-analysis of a randomized controlled trial

Author:

Gao Bing1,Li Lan1,Xia Ran1,qing-Li Ling1,Wang Zhu1,Wang Heng1,Cheng Yue1,Ma Qiang1,QI Zhuo Cao1,Wang Wei1,Zeng Yong Lei2,wang Jing1

Affiliation:

1. Anhui University of Chinese Medicine

2. The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine

Abstract

Abstract Background Moxibustion as an adjuvant therapy shows clinical efficacy in the treatment of heart failure (HF). However, there has been a lack of overall evaluation of the efficacy of moxibustion.Objective To evaluate the efficacy and safety of moxibustion combined with conventional drug therapy, and the quality of evidence regarding its use for preventing ventricular remodeling, improving cardiac function, and improving the prognosis of patients with HF.Method Search the keywords moxibustion therapy and HF from 7 databases. EndNote X8 software was used for literature management. RevMan 5.4.1 software was used to summarize data, and Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) was used to evaluate the quality of research.Results A total of 910 patients were included from 11 studies. Meta-analysis showed that compared with the control groups, patients treated with moxibustion had significantly improved 6-min walk experiment (6-MWD) scores (mean difference [MD] = 57.39, 95% confidence interval [CI] [39.49 to 75.30], P < 0.01) and left ventricular ejection fraction (LVEF) scores (MD = 4.93, 95% CI [3.12 to 6.74] for patients with HF, P < 0.01),According to GRADE, those using LVEF, Lee's HF score, and BNP were “moderate quality” and others were “low quality” or “very low quality.”Conclusion Studies suggest that moxibustion is a safe adjuvant treatment that can improve the cardiac function and prognosis of patients with HF. However, owing to the small sample sizes used in previous studies and the low quality of evidence, these results need to be further verified.

Publisher

Research Square Platform LLC

Reference39 articles.

1. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC;McDonagh TA;Eur J Heart Fail,2022

2. epidemiology, pathophysiology and prognosis of elderly heart failure Chinese;Li Shijun Advances in;J geriatric Cardiovasc Cerebrovasc Dis,2021

3. Heart Failure: Heart Failure With Preserved Ejection Fraction;Kane SF;FP essentials,2021

4. Ariyaratnam JP, Lau DH, Sanders P et al. Atrial Fibrillation and Heart Failure: Epidemiology, Pathophysiology, Prognosis, and Management. Cardiac electrophysiology clinics 2021; 13: 47–62. [5]Huang Congxin, Zhang Shu, Huang Dejia, Atrial fibrillation: current understanding and treatment recommendations – 2018. Chinese Journal of cardiac pacing and electrophysiology 2018; 32: 315–368.(in Chinese).

5. Li Xin and Feng Junjun Effect of moxibustion on cardiac function, BNP and CA125 in patients with heart failure of qi deficiency and blood stasis type Zhejiang;Jin;J Tradit Chin Med,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3